We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Foamix Pharmaceuticals Ltd | NASDAQ:FOMX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.99 | 2.80 | 4.00 | 0 | 01:00:00 |
FORM 3
|
Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person * Eini Meir |
2. Date of Event Requiring Statement (MM/DD/YYYY)
|
3. Issuer Name and Ticker or Trading Symbol Foamix Pharmaceuticals Ltd. [FOMX] |
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
_____ Officer (give title below) ___ X ___ Other (specify below) / Observer to Board of Directors |
|
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned |
|||
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Ordinary Shares | 2757781 | I | See footnote (1) |
Ordinary Shares | 11239 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Warrants | 5/13/2014 | 5/13/2018 | Ordinary Shares | 20860 | $5.04 | I | See footnote (1) |
Options | (2) | 12/29/2024 | Ordinary Shares | 48000 | $5.88 | D | |
Options | (3) | 12/29/2024 | Ordinary Shares | 36000 | $6.77 | D | |
Options | (4) | 8/9/2026 | Ordinary Shares | 35000 | $7.09 | D | |
Options | (5) | 1/1/2027 | Ordinary Shares | 60389 | $10.3 | D | |
Restricted Share Units | (6) | (6) | Ordinary Shares | 5625 | $0.00 | D | |
Restricted Share Units | (7) | (7) | Ordinary Shares | 20000 | $0.00 | D | |
Restricted Share Units | (8) | (8) | Ordinary Shares | 20130 | $0.00 | D |
Remarks:
The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018. Exhibit 24 Power of Attorney |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Eini Meir
2 HOLTZMAN STREET REHOVOT, L3 7670402 |
|
|
|
Observer to Board of Directors |
Signatures
|
||
/s/ Ilan Hadar as attorney-in-fact for Meir Eini | 1/18/2018 | |
** Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Foamix Pharmaceuticals Chart |
1 Month Foamix Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions